Contact
Gene Center
Laboratory for Translational Cancer Immunology
Ludwig-Maximilians-Universität München
Feodor-Lynen-Straße 25
81377 Munich
Germany
Laboratory for Translational Cancer Immunology
Ludwig-Maximilians-Universität München
Feodor-Lynen-Straße 25
81377 Munich
Germany
Room:
A 2.04
Phone:
+49 (0)89 - 4400 73133
Email:
marion.subklewe@med.uni-muenchen.de
Professional Experience
| Year | Function | Institute |
|---|---|---|
| since 2017 | Head of the Laboratory for Translational Cancer Immunology |
Gene Center Munich |
| since 2014 | Professor for Internal Medicine, with focus on Cellular Immunotherapy |
University Hospital, LMU Munich, Department of Medicine III |
| 2012-2017 | Head of the Clinical Cooperation Group "Immunotherapy" | Helmholtz Zentrum Munich |
| since 2009 | Head of Flow Cytometry, Laboratory of Leukemia Diagnostics |
University Hospital, LMU Munich, Department of Medicine III, Prof. Dr. W. Hiddemann |
| since 2009 | Consultant for Hematology / Oncology | University Hospital, LMU Munich, Department of Medicine III, Prof. Dr. W. Hiddemann |
| 2008-2009 | Clinical Fellow Hematology / Oncology | University Hospital, LMU Munich, Department of Medicine III, Prof. Dr. W. Hiddemann |
| 2000-2007 | Clinical Fellow Hematology / Oncology | The Charité, Campus Virchow-Klinikum, Medical Department III, Berlin, Prof. Dr. B. Dörken |
| 1996-2000 | Postdoctoral Fellow, DFG-Scholarship, Cure for Lymphoma Fellow |
Rockefeller University, New York, Prof. Dr. R. M. Steinman |
| 1995-1996 | Residency Internal Medicine | University Hospital Tübingen, Medical Department II, Hematology / Oncology / Reheumatology, Prof. Dr. L. Kanz |
Education
| 2014 | W2-Professor for Internal Medicine, with focus on Cellular Immunotherapy |
University Hospital, LMU Munich |
| 2007 | „Habilitation“ in Internal Medicine | Charité, Berlin |
| 2007 | Board Certification Hematology / Oncology | |
| 2005 | Board Certification Internal Medicine | |
| 1995 | Medical Dissertation | University of Cologne, Department of Internal Medicine, Hematology / Oncology, Prof. Dr. V. Diehl |
| 1988-1993 | Study of Medicine | University of Cologne |
| 1986-1988 | Study of Medicine | RWTH Aachen |
Awards and Honors
| 2015 | M4-Award: Startup support for the development of a novel multispecific antibody derivative |
| 2015 | ASH Abstract Achievement Award: Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE Antibody Construct (AMG 330) Mediated Cytotoxicity |
| 2014 | DGHO-Poster Prize: Addition of CD200 and Omission of sIgM Improves the Scoring System for the Diagnosis of CLL |
| 2013 | Selection for the ASH Highlights: Evaluation of CD33 expression and functional analysis of the CD33/CD3 bispecific antibody AMG 330 activity in primary AML samples |
| 2012 | Therese von Bayern-Award |
| 2011 | ASH Abstract Achievement Award: A Combined Score of Minimal Residual Disease (MRD) Assessment by Flow Cytometry, Cytogenetic and Molecular Markers As Well As Age Predicts Outcome and Can Potentially Guide MRD-Based Therapy in Acute Myeloid Leukemia |
| 2011 | ASH Abstract Achievement Award: Dendritic Cells Matured with a TLR7/8 Agonist Induce T Helper 1 Cell Polarization, Activate NK Cells and Are Thus Highly Suitable for Application in Cancer Immunotherapy |
| 2011 | Best Lecturer at the faculty of Medicine at the LMU |
| 2005-2007 | Rahel-Hirsch Scholarship at the Charité („Habilitations-Scholarship“) |
| 1999-2000 | Cure for Lymphoma Foundation Fellow |
| 1996-1999 | Postdoctoral Scholarship of the Deutsche Forschungsgemeinschaft |
Additional Functions
- Spokesman of the Else Kröner Clinician Scientist Programm Cancer Immunotherapy - LMU Munich, fostering the development of clinician scientists in oncology/immunology by a network of expert mentors, protected time for research, seminars and travel support
- Principal Investigator and Sponsor delegated Person of a prospective Phase I/II I-IT “Active immunotherapy of patients with AML using autologous dendritic cells transfected with RNA encoding leukemia-associated antigens”
- Principal Investigator of a Phase I Study „A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia“
- Principle Investigator in multiple Phase I trials (CAR T, T-cell recruiting antibodies), Principle Investigator in multiple Phase II/III trials in leukemia and lymphoma (GMALL, GLSG, DSHNHL)
- Protocol committee AML Cooperative Group (AML-CG)
- Member of the Organizing Committee of the International Symposium “Acute Leukemias” 2011; 2013; 2015; 2017
- Certification (2011) and Akkreditation Flow Cytometry (2012) within the Laboratory of Leukemia Diagnostics
- Collaborative Research Activities – Bavarian Immunotherapy Network, Helmholtz Alliance for Immunotherapy, Deutsches Konsortium für Translationale Krebsforschung, Munich Immunotherapy Consortium (MITC), Elitenetzwerk Bayern International Graduate School “Immunotargeting of Cancer”, SFB1243 “Cancer Evolution”, Else-Kröner Fresenius Forschungskolleg “Cancer Immunotherapy”
- Grant Reviews - Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; José-Carreras Stiftung; Wilhelm Sander Stiftung; Cancer Research UK; Leukemia and Lymphoma; OeGHO, Dutch Cancer Society, Wordwide Cancer Research
- Manuscript Reviews - Blood, Leukemia, Lancet Hematology, NEJM, PlosOne, J International Immunology, Journal of Hematology & Oncology; Haematologica; British Journal of Hematology
- Membership - Bund deutscher Internisten (BdI); European Association for Hematology (EHA); American Society for Hematology (ASH); Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO); Society for Immunotherapy of Cancer (SITC)
- Member of the “Research committee (Forschungskommission)” Klinikum der Universität München, member of several Thesis Advisory Committees